Anika Therapeutics, Inc.
NASDAQ:ANIK · NASDAQ Global Select
-$0.06 today
Vol 0.13M · Avg 0.11M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $41.0M |
| Receivables | $25.8M |
| Inventory | $22.8M |
| Other Current | $3.9M |
| Total Current Assets | $93.6M |
| PP&E (Net) | $65.2M |
| Goodwill | $7.9M |
| Intangible Assets | $1.6M |
| Long-term Investments | $5.7M |
| Tax Assets | $1.1M |
| Other Non-current | $4.3M |
| Total Non-current Assets | $85.8M |
| Total Assets | $179.4M |
Analysis
Selected assets total $179.4M for Latest. The largest visible component is PP&E (Net) at $65.2M, about 36.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $57.5M +3.3% | $55.6M -19.1% | $68.7M -20.4% | $86.3M -8.5% | $94.4M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $0 | $0 | $0 | $0 | $0 | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $23.7M +0.4% | $23.6M -10.5% | $26.4M -23.9% | $34.6M +16.0% | $29.8M | $533.8M | $399.4M | -$1.7B |
| Inventory | $18.8M -21.1% | $23.8M -2.5% | $24.4M -38.6% | $39.8M +10.4% | $36.0M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $3.4M -68.0% | $10.6M -75.7% | $43.8M | $0 | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $103.4M -9.1% | $113.7M -30.4% | $163.3M -3.7% | $169.5M +0.6% | $168.5M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $66.3M +2.4% | $64.7M -0.5% | $65.0M -17.7% | $79.0M +15.2% | $68.6M | $1.2B | $1.5B | $687.8M |
| Goodwill | $8.1M +13.0% | $7.1M -5.9% | $7.6M +3.2% | $7.3M -5.7% | $7.8M | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $1.6M -33.7% | $2.5M -3.3% | $2.6M -96.5% | $74.6M -9.4% | $82.4M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $1.3M +8.3% | $1.2M -21.0% | $1.5M +2.8% | $1.4M | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $9.7M -29.0% | $13.6M -55.6% | $30.7M +78.2% | $17.2M -15.1% | $20.3M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $86.9M -2.4% | $89.1M -17.0% | $107.3M -40.2% | $179.6M +0.3% | $179.0M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $190.3M -6.2% | $202.7M -25.1% | $270.6M -22.5% | $349.1M +0.5% | $347.5M | $13.3B | $11.9B | $10.6B |
| Account Payables | $6.0M +7.5% | $5.6M -9.3% | $6.2M -31.7% | $9.1M +18.9% | $7.6M | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 -100.0% | $63.0K -94.9% | $1.2M +53.1% | $810.0K | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $11.1M -8.7% | $12.2M -35.0% | $18.7M +65.7% | $11.3M -18.3% | $13.8M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $21.9M -6.0% | $23.3M -25.0% | $31.1M +11.3% | $27.9M -6.3% | $29.8M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $24.2M | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 -100.0% | $6.4M -36.6% | $10.2M | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $701.0K -51.0% | $1.4M +2.7% | $1.4M +250.0% | $398.0K -68.4% | $1.3M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $24.9M -2.2% | $25.4M -6.8% | $27.3M -23.4% | $35.7M +16.3% | $30.7M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $46.8M -4.0% | $48.8M -16.5% | $58.4M -8.2% | $63.6M +5.2% | $60.5M | $14.7B | $3.7B | $9.6B |
| Common Stock | $139.0K -3.5% | $144.0K -2.0% | $147.0K +0.7% | $146.0K +1.4% | $144.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $60.8M -15.2% | $71.7M -44.0% | $128.1M -39.2% | $210.7M -6.6% | $225.6M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$5.0M +26.9% | -$6.8M -14.1% | -$5.9M +7.8% | -$6.4M -12.7% | -$5.7M | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $143.5M -6.8% | $154.0M -27.5% | $212.3M -25.7% | $285.6M -0.5% | $287.1M | $9.1B | $7.7B | $3.3B |
| Total Debt | $26.2M +1.2% | $25.9M -6.5% | $27.7M -10.2% | $30.9M +47.4% | $21.0M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$31.2M -5.2% | -$29.7M +27.6% | -$41.0M +26.0% | -$55.4M +24.5% | -$73.4M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$348.39M
Apyx Medical Corporation
NASDAQ:APYX
$172.82M
Quipt Home Medical Corp.
QIPT
$162.30M
MaxCyte, Inc.
NASDAQ:MXCT
$125.87M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$104.86M
Owlet, Inc.
NYSE:OWLT
$91.38M
Anixa Biosciences, Inc.
NASDAQ:ANIX
$89.65M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$77.27M
LENSAR, Inc.
NASDAQ:LNSR
$71.05M
Accuray Incorporated
ARAY
$40.67M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ANIK have?
Anika Therapeutics, Inc. (ANIK) reported $57.48M in cash and equivalents in fiscal 2025.
How much debt does ANIK carry?
Anika Therapeutics, Inc. (ANIK) reported $26.25M of total debt, with net debt of -$31,233,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.